Cardiac iron overload evaluation in thalassaemic patients using T2* magnetic resonance imaging following chelation therapy: a multicentre cross-sectional study
Eduardo Cerello Chapchap,Murilo Marques Almeida Silva,Reijane Alves de Assis,Lucila Nassif Kerbauy,Michelli da Silva Diniz,Laércio Alberto Rosemberg,Sandra Regina Loggetto,Aderson da Silva Araujo,Antonio Fabron,Monica Pinheiro de Almeida Verissimo,Giorgio Roberto Baldanzi,Breno Pannia Esposito,Fernando Tricta,Merula Emmanoel Anargyrou Steagall,Claudia Ângela Galleni Di Sessa Vellozo,Kleber Yotsumoto Fertrin,Ronaldo Hueb Baroni,Nelson Hamerschlak,Antonio Fabron Junior
DOI: https://doi.org/10.1016/j.htct.2021.01.014
2021-05-01
Hematology, Transfusion and Cell Therapy
Abstract:INTRODUCTION: Magnetic resonance imaging (MRI) T2* technique is used to assess iron overload in the heart, liver and pancreas of thalassaemic patients. Optimal iron chelation and expected tissue iron response rates remain under investigation. The objective of this study was to analyse serum ferritin and the iron concentration in the heart, liver and pancreas measured by MRI T2*/R2* during regular chelation therapy in a real-world cohort of patients with thalassemia.METHODS: We evaluated thalassaemic patients ≥ 7 years old undergoing chelation/transfusion therapy by MRI and assessed serum ferritin at baseline and follow-up from 2004-2011.RESULTS: We evaluated 136 patients, 92% major thalassaemic, with a median age of 18 years, and median baseline ferritin 2.033ng/ml (range: 59-14,123). Iron overload distribution was: liver (99%), pancreas (74%) and heart (36%). After a median of 1.2 years of follow-up, the iron overload in the myocardium reduced from 2,63 Fe mg/g to 2,05 (p 0.003). The optimal R2* pancreas cut-off was 148 Hertz, achieving 78% sensitivity and 73% specificity. However, when combining the R2* pancreas cut off ≤ 50 Hertz and a ferritin ≤ 1222 ng/ml, we could reach a negative predictive value (NPV) of 98% for cardiac siderosis. Only 28% were undergoing combined chelation at baseline assessment, which increased up to 50% on follow up evaluation.CONCLUSIONS: Chelation therapy significantly reduced cardiac siderosis in thalassaemic patients. In patients with moderate/severe liver iron concentration undergoing chelation therapy, ferritin levels and myocardium iron improved earlier than the liver siderosis.